|
|
RICHMOND HILL, ON / ACCESSWIRE / April 21, 2022 / Helix BioPharma Corp. TSX:HBP "Helix" or the "Company", a clinicalstage biopharmaceutical company developing unique therapies in the field of immunooncology, based on its proprietary technological platform DOS47, today announces that it has closed a private placement financing for net proceeds of $2,002,000 from the issuance of... Lire le communiqué |
|
| |
|
| |
|
|
RICHMOND HILL, ON / ACCESSWIRE / April 18, 2022 / Helix BioPharma Corp. TSX:HBP "Helix" or the "Company", a clinicalstage biopharmaceutical company developing unique therapies in the field of immunooncology, based on its proprietary technological platformDOS47, is pleased to announce that Artur Gabor has been appointed as the Companys Chief Executive Officer with immediate... Lire le communiqué |
|
| |
|
| |
|
|
RICHMOND, ON / ACCESSWIRE / April 13, 2022 / Helix BioPharma Corp. TSX:HBP "Helix" or the "Company", a clinicalstage biopharmaceutical company developing unique therapies in the field of immunooncology, based on its proprietary technological platform DOS47, is pleased to announce that it has received conditional approval from the Toronto Stock Exchange the "TSX" to... Lire le communiqué |
|
| |
|
| |
|
|
RICHMOND HILL, ON / ACCESSWIRE / April 7, 2022 / Helix BioPharma Corp. TSX:HBP "Helix" or the "Company", a clinicalstage biopharmaceutical company developing unique therapies in the field of immunooncology, based on its proprietary technological platform DOS47, today announced the resignation of Dr. Krzysztof Saczek from the Board of Directors with immediate effect.... Lire le communiqué |
|
| |
|
| |
|
|
RICHMOND HILL, ON / ACCESSWIRE / March 22, 2022 / Helix BioPharma Corp. TSX:HBP "Helix" or the "Company", a clinicalstage biopharmaceutical company developing unique therapies in the field of immunooncology, based on its proprietary technological platform DOS47, today announced that Frank Michalargias has notified the Board of Directors of the Company of his intention to... Lire le communiqué |
|
| |
|
| |
|
|
RICHMOND, ON / ACCESSWIRE / March 16, 2022 / Helix BioPharma Corp. TSX:HBP, " Helix " or the " Company ", a clinicalstage biopharmaceutical company developing unique therapies in the field of immunooncology based on its proprietary technological platform DOS47, today announced fiscal 2022 second quarter results for the period ending January 31, 2022.... Lire le communiqué |
|
| |
|
| |
|
|
RICHMOND HILL, ON / ACCESSWIRE / March 16, 2022 / Helix BioPharma Corp. TSX:HBP "Helix" or the "Company" today announces, with great sadness, the sudden passing of its Interim Chief Executive Officer and Chairman of the Board of Directors the "Board", Prof. Dr. S Slawomir Majewski.Dr. Majewski has been on the Board since 2012 and has led... Lire le communiqué |
|
| |
|
| |
